{
    "clinical_study": {
        "@rank": "23603", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Compare conjugated bilirubin levels and serum bile acid levels in severely\n      premature newborns on long term parenteral nutrition and given either sincalide or placebo.\n\n      II.  Compare morbidity and mortality rates in this patient population. III.  Evaluate\n      ultrasonographic images of the hepatobiliary tree during and 1 to 2 years after the\n      administration of sincalide or placebo to assess the development of biliary sludge and\n      biliary stone formation."
        }, 
        "brief_title": "Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis", 
        "condition": "Cholestasis", 
        "condition_browse": {
            "mesh_term": "Cholestasis"
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, placebo controlled, double blind, multicenter study.\n      Patients are stratified according to prematurity or surgical group.\n\n      Patients are randomized to receive either placebo or sincalide IV over 10 to 15 minutes\n      every 12 hours until a total of 8 weeks of therapy is administered or greater than 50% of\n      their nutrition is enteral.\n\n      Patients are followed for a maximum of 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics-- Severely premature neonates (less than 1000 g at birth and\n        estimated gestational age of no greater than 28 weeks) that require greater than 50% of\n        caloric requirements by parenteral means within 7 days of birth OR Neonates with one or\n        more of the following surgical conditions: Necrotizing enterocolitis Gastroschisis Severe\n        jejunal-ileal atresia within 7 days of diagnosis --Prior/Concurrent Therapy-- Biologic\n        therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Not specified\n        Radiotherapy: Not specified Surgery: See Disease Characteristics No other cardiovascular\n        (thoracotomy) or major gastrointestinal surgery (laparotomy) during the newborn period\n        Other: No prior or concurrent ursodeoxycholic acid No concurrent use of extracorporeal\n        life support --Patient Characteristics-- Performance status: Not specified Hematopoietic:\n        Not specified Hepatic: Conjugated bilirubin no greater than 1.0 mg/dL No primary or\n        secondary liver disease No hepatic insufficiency as documented by either a biopsy with\n        cirrhosis or elevated prothrombin time without evidence of systemic coagulopathy and no\n        administration of an anticoagulant Renal: No renal failure as indicated by a progressive\n        increase in creatinine levels Other: No hemodynamic instability No documented communicable\n        infection (including infectious hepatitis or HIV) No metabolic pathway defect that is\n        associated with liver dysfunction in the neonatal period including hereditary fructose\n        intolerance, galactosemia due to transferase deficiency, and neonatal tyrosinemia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "30 Days", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "252", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004414", 
            "org_study_id": "199/13306", 
            "secondary_id": "UMMS-FDR001449"
        }, 
        "intervention": {
            "intervention_name": "sincalide", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "cholestasis", 
            "gastrointestinal disorders", 
            "rare disease"
        ], 
        "lastchanged_date": "September 6, 2006", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21231"
                    }, 
                    "name": "Johns Hopkins Oncology Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109-0718"
                    }, 
                    "name": "University of Michigan Medical School"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14642"
                    }, 
                    "name": "University of Rochester Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45229-3039"
                    }, 
                    "name": "Children's Hospital Medical Center - Cincinnati"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Providence", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02903"
                    }, 
                    "name": "Rhode Island Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }, 
                    "name": "Baylor University Medical Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "University of Michigan", 
            "last_name": "Daniel Hillel Teitelbaum", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004414"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Michigan", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "September 1997", 
        "study_design": "Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 1999"
    }, 
    "geocoordinates": {
        "Baylor University Medical Center": "32.803 -96.77", 
        "Children's Hospital Medical Center - Cincinnati": "39.103 -84.512", 
        "Johns Hopkins Oncology Center": "39.29 -76.612", 
        "Rhode Island Hospital": "41.824 -71.413", 
        "University of Michigan Medical School": "42.281 -83.743", 
        "University of Rochester Medical Center": "43.161 -77.611"
    }
}